Evidence map›Paper›PMID 31633004›Full record

ArticleAdvanced biosystems2019

Supporting Survival of Transplanted Stem-Cell-Derived Insulin-Producing Cells in an Encapsulation Device Augmented with Controlled Release of Amino Acids.

Gauree S Chendke, Gaetano Faleo, Charity Juang, Audrey V Parent, Daniel A Bernards, Matthias Hebrok, Qizhi Tang, Tejal A Desai

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biosystems, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gauree S ChendkeDepartment of Bioengineering and Therapeutic Sciences, University of California, 1700 4th Street, Byers Hall, Box 2520, San Francisco, CA 94158, USA.
Gaetano FaleoDepartment of Surgery, University of California, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
Charity JuangUCSF Diabetes Center, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
Audrey V ParentUCSF Diabetes Center, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
Daniel A BernardsDepartment of Bioengineering and Therapeutic Sciences, University of California, 1700 4th Street, Byers Hall, Box 2520, San Francisco, CA 94158, USA.
Matthias HebrokUCSF Diabetes Center, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
Qizhi TangDepartment of Surgery, University of California, 513 Parnassus Avenue, San Francisco, CA 94143, USA.
Tejal A DesaiDepartment of Bioengineering and Therapeutic Sciences, University of California, 1700 4th Street, Byers Hall, Box 2520, San Francisco, CA 94158, USA.
University of California, San Francisco · USUniversity of California San Francisco Medical Center · US

Funding

UCSF/UCB Joint Graduate Group in BIoengineeringT32GM008155 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A. · 1985 to 2020
$12.2M
NIGMS NIH HHS T32 GM008155
6 · The paper itself

Abstract

Pancreatic islet transplantation is a promising treatment for type I diabetes, which is a chronic autoimmune disease in which the host immune cells attack insulin-producing beta cells. The impact of this therapy is limited due to tissue availability and dependence on immunosuppressive drugs that prevent immune rejection of the transplanted cells. These issues can be solved by encapsulating stem cell-derived insulin-producing cells in an immunoprotective device. However, encapsulation exacerbates ischemia, and the lack of vasculature at the implantation site post-transplantation worsens graft survival. Here, an encapsulation device that supplements nutrients to the cells is developed to improve the survival of encapsulated stem cell-derived insulin-producing cells in the poorly vascularized subcutaneous space. An internal compartment in the device is fabricated to provide zero-order release of alanine and glutamine for several weeks. The amino acid reservoir sustains viability of insulin-producing cells in nutrient limiting conditions in vitro. Moreover, the reservoir also increases cell survival by 30% after transplanting the graft in the subcutaneous space.

Indexed as

beta cell replacement therapycell encapsulation devicenanotechnologytransplantationtype 1 diabetes

Identifiers

PMID31633004
PMCPMC6800235
OpenAlexW2967339904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.